Upper Respiratory Tract Infections Clinical Trial
Official title:
Randomized Controlled Trial of a Homeopathic Cold Remedy for Children
| Verified date | December 2014 |
| Source | University of Washington |
| Contact | n/a |
| Is FDA regulated | No |
| Health authority | United States: Institutional Review Board |
| Study type | Interventional |
A randomized controlled trial of a commercially available homeopathic cold remedy will be conducted. A total of 400 children, 2-5 years old, diagnosed with an upper respiratory tract infection will be randomized to receive either the homeopathic remedy or placebo. Parents of study children will administer 5 ml of the study medication up to 6 times per day as needed to treat cold symptoms. One hour after giving a dose the parent will rate change in symptoms (for up to the first 10 doses). In addition, parents will rate their child's overall symptom severity and functional status over the first 3 days of the cold. It is postulated that children receiving the active homeopathic remedy will have better symptom relief and that their symptom severity and functional status will improve more rapidly than those receiving placebo.
| Status | Completed |
| Enrollment | 263 |
| Est. completion date | December 2013 |
| Est. primary completion date | August 2013 |
| Accepts healthy volunteers | No |
| Gender | Both |
| Age group | 2 Years to 5 Years |
| Eligibility |
Inclusion Criteria: - clinical diagnosis of upper respiratory tract infection - duration of symptoms < 7 days - Parent who speaks English Exclusion Criteria: - history of asthma - on any prescribed medication - prescribed any medication other than acetaminophen or ibuprofen at index visit - use of homeopathic remedy within 48 hours of index visit |
Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment
| Country | Name | City | State |
|---|---|---|---|
| United States | University of Washington Medical Center- Roosevelt Pediatric Care Center | Seattle | Washington |
| Lead Sponsor | Collaborator |
|---|---|
| University of Washington | Standard Homeopathic Company |
United States,
| Type | Measure | Description | Time frame | Safety issue |
|---|---|---|---|---|
| Primary | Change in Severity of Cold Symptoms | Parents measured change in runny nose, cough, nasal congestion and sneezing severity one hour after administering a dose of study medication up to the first 10 doses of study medication. Change in symptom rated from 0 to 6, with 0 indicative of the symptom being much worse and 6 indicative of the symptom being much improved. The unit of analysis for each outcome was doses of medication. Each participant could contribute data on 0 - 10 doses. | Parents assessed change in symptom 1 hour after a dose of study medication | No |
| Secondary | Change in Non-specific Symptoms | Parents measured change in severity of irritability, lethargy, fussiness, and appetite one hour after administering a dose of study medication up to the first 10 doses of study medication. Change in symptom rated from 0 to 6, with 0 indicative of the symptom being much worse and 6 indicative of the symptom being much improved. The unit of analysis for each outcome was doses of medication. Each participant could contribute data on 0 - 10 doses. | Parents assessed change in symptom 1 hour after dose of study medication | No |
| Secondary | Functional Status | Change in functional status of child during the 7-10 days after the index visit for an upper respiratory tract infection. Parents rated 5 activities (vigorous activity, activities that require concentration, activities with family or friends, appetite and sleep) daily for 3 days in their child and again at the 7-10 day follow-up. Functional status scores range from 0 to 15, with higher scores indicative of better functional status. | 10 days | No |
| Secondary | Health Status | Change in health status of child during the 7-10 days after the index visit for an upper respiratory tract infection. Parents rated health status on 1-10 scale with 1 indicating perfect health and 10 indicating very sick. Health status rated on first 3 days of study and again at the 7-10 day follow-up | 10 days | No |
| Secondary | Overall Symptom Severity | Change in cold symptoms of child during the 7-10 days after the index visit for an upper respiratory tract infection. Parents assessed severity of runny nose, cough, sneeze and congestion in their child using a 0-3 scale for each symptom, 0=none to 3= severe. Cold score is sum of scores for each symptom. Parents assessed cold score twice daily on study days 1-3 and at the 7-10 day follow-up | 10 days | No |
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT01158560 -
A Trial of Vitamin D and Health Advice for the Prevention of Upper Respiratory Tract Infections
|
Phase 3 | |
| Completed |
NCT00965822 -
A Randomized, Double-blind, Placebo-controlled Study on the Efficacy and Safety of CVT-E002 in the Treatment of Upper Respiratory Tract Infections in a Pediatric (3-11 Years) Population
|
Phase 2 | |
| Completed |
NCT01019889 -
Effect of Socheongryong-tang and Yeongyopaedok-san in Upper Respiratory Tract Infection
|
Phase 3 | |
| Not yet recruiting |
NCT05484102 -
Preventive Effect of Cow's Milk Fermented With Lactobacillus Paracasei CBA L74 on Common Infectious Diseases in Children
|
N/A | |
| Recruiting |
NCT05804123 -
LiveSpo Navax® Supports the Treatment of Acute Rhinosinusitis and Otitis Media
|
N/A | |
| Terminated |
NCT01964885 -
Benefit and Tolerability of IQP-AS-105 in Reducing Susceptibility to Upper Respiratory Tract Infections
|
Phase 3 | |
| Completed |
NCT01773824 -
Routine Prescription Feedback and Peer Comparison to Lower Antibiotic Prescriptions in Primary Care
|
N/A | |
| Completed |
NCT01883427 -
Nasal Spray With Glucose Oxidase Preventing Common Cold in Pre-school Children
|
Phase 2 | |
| Completed |
NCT01215682 -
Vitamin D Supplementation and Upper Respiratory Tract Infections in Adolescent Swimmers
|
N/A | |
| Completed |
NCT04019730 -
The Effect of a Ketogenic Diet on the Exercise Induced Immune Response
|
N/A | |
| Completed |
NCT01604096 -
Controlled Trial to Evaluate a Local Information Campaign on Antibiotic Prescribing in Italy
|
Phase 2 | |
| Recruiting |
NCT06149494 -
RCT of Vapendavir in Patients With COPD and Human Rhinovirus/Enterovirus Upper Respiratory Infection
|
Phase 2 | |
| Completed |
NCT03463694 -
Edinburgh and Lothian Virus Intervention Study in Kids
|
N/A | |
| Completed |
NCT06127186 -
Phenotype of Headache and Facial Pain in Upper Respiratory Tract Infections
|
||
| Completed |
NCT03198676 -
A Safety Study to Compare the Effect of Two PrEP-001 Nasal Powder Formulations on Nasal Mucosa and Serum Cytokine Production
|
Phase 1 | |
| Withdrawn |
NCT05557214 -
Reducing Unnecessary Antibiotic Prescriptions in Primary Healthcare in Saskatchewan by Identifying High Prescribers
|
N/A | |
| Completed |
NCT01893762 -
Innate Immune Response to (An)Aerobic Exercise in Rowing Athletes
|
N/A | |
| Completed |
NCT01396889 -
Impact of Echinacea as Prophilaxis for Upper Respiratory Tract Infections in Children 1-5 Years
|
N/A | |
| Completed |
NCT01129128 -
Three Arm Trial of Immune Effects of Echinacea
|
N/A | |
| Completed |
NCT05252468 -
COVID-19 Prevention Trial: Effect of Prophylactic Use of TAFFIX™ on Infection Rate by SARS-CoV-2 Virus (COVID-19).
|
N/A |